Wolozin is a member of Evans Center for Interdisciplinary Biomedical Research and Genome Science Institute in Boston University.

He is also co-founder and Chief Scientific Officer (CSO) of Aquinnah Pharmaceuticals Inc., a biotechnology company developing novel therapeutics to treat Alzheimer's disease, and Amyotrophic Lateral Sclerosis.

His research examines molecular and cellular aspects of disease, and utilizes a variety of transgenic models including mice, C. elegans, primary neurons and cell lines.

[11] A highly unusual and important aspect of these proteins is that they use reversible aggregation as normal biological mechanism to sequester RNA transcripts.

[13] Since then, a growing body of evidence, increasingly highlights the important contributions of RNA-binding proteins (RBPs), stress granules and translational regulation in the pathophysiology of neurodegenerative disease.

[14] LLPS occurs when RNA binding proteins associate to form structures analogous to liquid droplets, which separate from surrounding aqueous medium.

[17][18] This appears to occur because tau (the main building block of neurofibrillary tangles) stimulates stress granule formation.

Stress granules appear able to stimulate tau pathology, leading to the hypothesis that Alzheimer's disease occurs in part because of a hyperactive stress granule response stimulated by chronic diseases and/or genetic changes, which results in abundant tau pathology and subsequent neurodegeneration.